Site Map
QUADRAMET® causes bone marrow suppression. Before QUADRAMET is administered, consideration should be given to the patient's current clinical and hematologic status and bone marrow response history to treatment with myelotoxic agents. Because of the unknown potential for additive effects on bone marrow, QUADRAMET should not be given concurrently with chemotherapy or external beam radiation therapy unless the clinical benefits outweigh the risks.
Home | EUSA Pharma | Safety Information | Prescribing Information | Reimbursement Information
Freedom To Do More | Bone Metastases | Patient Types | News & Clinical Updates | Patient Resources | Web Resources
Contact Us | Site Map | Privacy Policy | Terms of Use
Copyright © 2010 EUSA Pharma (USA), Inc. All rights reserved
Q-0262-07